Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA3 | P07451 | 1/20 | 0.30 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
| ▸ | CA6 | P23280 | 1/20 | 0.30 |
| ▸ | CA5A | P35218 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5675071 | 0.76 | — | — | |
| SCHEMBL23846218 | 0.76 | HTR2A (0.34) | HTR2AHRH1ALDH1A1TSHRTDP1 | |
| SCHEMBL10678873 | 0.76 | HTR2A (0.34) | HTR2AHRH1ALDH1A1TSHRTDP1 | |
| SCHEMBL16321282 | 0.74 | ALDH1A1 (0.30) | ALDH1A1TSHR | |
| SCHEMBL19810525 | 0.74 | MAPT (0.41) | HTR2AHRH1ALDH1A1TSHRTDP1 | |
| SCHEMBL11690029 | 0.74 | DNM1 (0.36) | HTR2AHRH1ALDH1A1TSHRTDP1 | |
| SCHEMBL30761776 | 0.74 | ALDH1A1 (0.43) | HTR2AHRH1ALDH1A1TSHRTDP1 | |
| SCHEMBL30792552 | 0.74 | HTR2A (0.33) | HTR2AHRH1ALDH1A1TSHRTDP1 | |
| SCHEMBL11682459 | 0.72 | HTR2A (0.32) | HTR2AHRH1 | |
| SCHEMBL2454883 | 0.72 | MAPT (0.46) | HTR2AHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102174161-A | Polyurethane foaming catalyst and synthesis method thereof | ZHANGJIAGANG CITY DAWEI ASSISTANTS INDUSTRY CO LTD | 2011-09-07 | — | — | CN | claimed |
| EP-0239191-A2 | Pyrazolo[4,3-b]pyridine derivatives, process for their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1987-09-30 | — | — | EP | claimed |
| US-10023863-B2 | Therapeutics with conformationally restricted monomers | MARINA BIOTECH, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-9751909-B2 | Synthesis and uses of nucleic acid compounds with conformationally restricted monomers | MARINA BIOTECH, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| WO-2017115329-A1 | C-3 NOVEL TRITERPENONE DERIVATIVES AS HIV INHIBITORS | HETERO RESEARCH FOUNDATION (IN) | 2017-07-06 | — | — | WO | disclosed |
| US-20150315591-A1 | NICKED OR GAPPED NUCLEIC ACID MOLECULES AND USES THEREOF | MARINA BIOTECH, INC. (US) | 2015-11-05 | — | — | US | disclosed |
| US-20150284717-A1 | OLIGOMERS WITH CONFORMATIONALLY RESTRICTED MONOMERS AND UNLOCKED NUCLEOMONOMERS | MARINA BIOTECH INC (US) | 2015-10-08 | — | — | US | disclosed |
| US-20150258130-A1 | NICKED OR GAPPED NUCLEIC ACID MOLECULES AND USES THEREOF | MARINA BIOTECH, INC. (US) | 2015-09-17 | — | — | US | disclosed |
| US-20150259686-A1 | NICKED OR GAPPED NUCLEIC ACID MOLECULES AND USES THEREOF | MARINA BIOTECH, INC. (US) | 2015-09-17 | — | — | US | disclosed |
| US-9074205-B2 | Nicked or gapped nucleic acid molecules and uses thereof | MARINA BIOTECH, INC. (US) | 2015-07-07 | — | — | US | disclosed |
| US-20150080564-A1 | SYNTHESIS AND USES OF NUCLEIC ACID COMPOUNDS WITH CONFORMATIONALLY RESTRICTED MONOMERS | MARINA BIOTECH, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| EP-1122245-A2 | 2-Amino-benzoxazinones for the treatment of viral infections | G.D. Searle & Co. (US) | 2001-08-08 | — | — | EP | disclosed |
| WO-2001003697-A1 | 2-AMINO-BENZOXAZINONES FOR THE TREATMENT OF HERPES SIMPLEX VIRUS | G.D. SEARLE & CO. (US) | 2001-01-18 | — | — | WO | disclosed |
| US-5985872-A | THERAPEUTIC TREATMENT OF HERPES VIRAL INFECTION | G.D. SEARLE & CO. (US) | 1999-11-16 | — | — | US | disclosed |
| CN-1190387-A | Process for preparation of tertiary aminocarbonates and aminoethers | OSI SPECIALTIES INC (US) | 1998-08-12 | — | — | CN | disclosed |
| EP-0659761-B1 | New 17-iminomethylalkenyl-5beta-14beta-androstane and 17-iminoalkyl-5beta-14beta-androstane derivatives active on the cardiovascular system, processes for their preparation and pharmaceutical compositions containing same | SIGMA TAU IND FARMACEUTI (IT) | 1998-04-22 | — | — | EP | disclosed |
| EP-0828721-A1 | 2-AMINO-BENZOXAZINONES FOR THE TREATMENT OF VIRAL INFECTIONS | G.D. SEARLE & CO. (US) | 1998-03-18 | — | — | EP | disclosed |
| WO-1996037485-A1 | 2-AMINO-BENZOXAZINONES FOR THE TREATMENT OF VIRAL INFECTIONS | G.D. SEARLE & CO. (US) | 1996-11-28 | — | — | WO | disclosed |
| EP-0659761-A2 | New 17-iminomethylalkenyl-5beta-14beta-androstane and 17-iminoalkyl-5beta-14beta-androstane derivatives active on the cardiovascular system, processes for their preparation and pharmaceutical compositions containing same | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1995-06-28 | — | — | EP | disclosed |
| EP-0239191-A2 | Pyrazolo[4,3-b]pyridine derivatives, process for their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1987-09-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315591-A1 | NICKED OR GAPPED NUCLEIC ACID MOLECULES AND USES THEREOF | RNMT, POLRMT, SNRPE | HTR2A 3795/4885HRH1 4556/4885ALDH1A1 3495/4885 |
| US-20150080564-A1 | SYNTHESIS AND USES OF NUCLEIC ACID COMPOUNDS WITH CONFORMATIONALLY RESTRICTED MONOMERS | POLN, NSUN2, POLM | HTR2A 3150/4885HRH1 3869/4885ALDH1A1 4544/4885 |
| US-20150258130-A1 | NICKED OR GAPPED NUCLEIC ACID MOLECULES AND USES THEREOF | RNMT, POLRMT, SNRPE | HTR2A 3795/4885HRH1 4556/4885ALDH1A1 3495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.